Iron therapy

Identifying and treating iron deficiency in patients hospitalized for heart failure

Identifying and treating iron deficiency in patients hospitalized for heart failure

By Hans Haag and Dr. Ricky Turgeon on July 5, 2023

Heart failure is the third leading cause of hospitalization in Canada and leads to readmission in 1 in 5 patients within 30 days after discharge. Iron deficiency (with or without anemia) is an important comorbidity in patients with HF and is associated with worse outcomes. Assess iron deficiency for all patients with HFrEF and HFmrEF admitted for acute HF.

New study on the use of erythropoietin stimulating agents in chronic kidney disease has made us evaluate the risk-benefit of ESA’s in CKD patients not on dialysis.

By Dr. Monica Beaulieu on June 14, 2010

The evidence strongly suggests that there is little to no benefit gained by raising the Hb over > 100g/L (and perhaps even lower) in diabetic patients with CKD not on dialysis.

Visit UBC CPD at ubccpd.ca

UBC CPD website

View all CPD learning activities: virtual, in-person and hybrid conferences, workshops, webinars, online modules, customized community courses, simulation hands-on courses, coaching, mentoring, personalized learning, recordings, and more.

Visit UBC CPD ↗

This field is for validation purposes and should be left unchanged.